NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Apnimed, Inc. (APMD) Stock Analysis

Apnimed, Inc. (APMD) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

APMD

$27.45

−$0.36 (−1.29%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare APMD with… →

APMD Key Statistics

As of Sep 4, 2026
Trading
Open
$27.36
Previous Close
$27.81
Day's Range
26.44–28.36
52-Week Range
16.12–35.29
Volume
232.90K
Valuation
Market Cap
$1.14B
P/E Ratio
11.39
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
9.51
EPS (ttm)Profit attributable to each share over the last twelve months.
2.41
Financials (FY)
Revenue (FY)
$38.47M+380.12%
Net Income (FY)
−$932.00K
Profit marginThe share of revenue left as profit after all costs and taxes.
−26.49%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
41.62M
Dividend and dates
Avg Volume
507.06K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

APMD Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$38.47M−$932.00K−2.4%
2024$8.01M−$111.31M−1389.2%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$38.47M$31.77M−$53.82M−$932.00K−2.4%
2024$8.01M$4.64M−$114.23M−$111.31M−1389.2%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

APMD Valuation vs Biotechnology Median

Median of 656 stocks
MetricAPMDBiotechnology medianvs median
P/E11.3912.579% below
P/S ratio9.5115.2638% below
Profit margin−26.49%0.00%26.5 pts below

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Apnimed, Inc. (APMD) at $1.14B. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 65 employees.

The most recent close on file for APMD is $27.45, dated September 4, 2026. That is −$0.36 (−1.29%) against the previous close. Over the past 52 weeks the price has ranged from $16.12 to $35.29. The latest close sits 70.29% above that 52-week low.

Financial Health

In fiscal 2025, Apnimed, Inc. reported revenue of $38.47M. Against the prior fiscal year total of $8.01M, that is a change of +380.12%. The same year closed with a net loss of $932.00K. Profit margin runs at −26.49%. That is 26.5 percentage points below the Biotechnology median of 0%. Trailing earnings per share are 2.41.

Valuation Assessment

APMD trades at a trailing price-to-earnings ratio of 11.39. That is 9.39% below the Biotechnology median of 12.57. The price-to-sales ratio is 9.51. On price-to-sales that is 37.7% below the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

Growth & Income

The record shows no dividend for APMD.

So far in 2026 the price is +9.80%.

Peer Comparison

Apnimed, Inc. (APMD) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Apnimed, Inc. APMD $1.14B 11.4
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Apnimed, Inc. trades at a P/E of 11.4.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Apnimed, Inc.

Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets. It offers AD109, an oral therapy designed to treat obstructive sleep apnea (OSA) by targeting the underlying neuromuscular dysfunction. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Visit website →